2 subgroups of patients through cluster analysis.

- 4 Mienke Rijsdijk^{1*}, Hidde M. Smits², Hazal R. Azizoglu¹, Sylvia Brugman³, Yoeri van de
- 5 Burgt⁴ Tessa C. van Charldorp⁵, Dewi J. van Gelder⁶, Janny C. de Grauw⁷ Eline A. van
- 6 Lange⁸, Frank J. Meye⁹, Madelijn Strick¹⁰, Hedi Walravens¹, Laura H.H. Winkens⁶, Frank
- Huygen^{1,8}, Julia Drylewicz², Hanneke L.D.M. Willemen².

9 Affiliations

1

3

- 10 1. Pain Clinic, Department of Anesthesiology, University Medical Center Utrecht,
- 11 Utrecht University, Utrecht, The Netherlands.
- 12 2. Center for Translational Immunology (CTI), University Medical Center Utrecht,
- 13 Utrecht University, Utrecht, The Netherlands.
- 14 3. Wageningen University and Research, Animal Sciences Group, Host Microbe
- 15 Interactomics, Wageningen, the Netherlands
- 4. Microsystems, Institute for Complex Molecular Systems, Eindhoven University of
- 17 Technology, Netherlands
- 18 5. Languages, Literature and Communication, Faculty of Humanities, Utrecht
- 19 University, Utrecht, the Netherlands.
- 20 6. Consumption and Healthy Lifestyles Chair group, Wageningen University and
- 21 Research, Wageningen, The Netherlands.

39

40

41

42

Number of figures: 2

Number of tables: 5

Abstract

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

Background: Chronic pain is an ill-defined disease with complex biopsychosocial aspects, posing treatment challenges. We hypothesize that treatment failure results, at least partly, from limited understanding of diverse patient subgroups. We aim to identify subgroups through psychometric data, allowing for more tailored interventions. Methods: For this retrospective cohort study, we extracted patient-reported data from two Dutch tertiary multidisciplinary outpatient pain clinics (2018-2023) for unsupervised hierarchical clustering. Clusters were defined by anxiety, depression, pain catastrophizing, and kinesiophobia. Sociodemographics, pain characteristics, diagnosis, lifestyle, healthrelated quality of life (HRQoL) and treatment efficacy were compared among clusters. A prediction model was built utilizing a minimum set of questions to reliably assess cluster allocation. **Results:** Among 5,454 patients with chronic pain, three clusters emerged. Cluster 1 (n=750) was characterized by high psychological burden, low HRQoL, lower educational levels and employment rates, and more smoking. Cluster 2 (n=1,795) showed low psychological burden, intermediate HROoL, higher educational levels and employment rates, and more alcohol consumption. Cluster 3 (n=2,909) showed intermediate features. Pain reduction following treatment was least in cluster 1 (28.6% after capsaicin patch, 18.2% after multidisciplinary treatment), compared to >50% in clusters 2 and 3. A model incorporating 15 psychometric questions reliably predicted cluster allocation. In conclusion, our study identifies distinct chronic pain patient clusters through 15 psychometric questions, revealing one cluster with notably poorer response to conventional treatment. Our prediction model may help clinicians improve treatment by allowing patient-

subgroup targeted therapy according to cluster allocation.

In brief
Hierarchical clustering of chronic pain patients revealed three clusters based on pain
experience and psychological welfare, with diverse sociodemographics and treatment effects
suggesting potential for tailored interventions.
Keywords: Chronic pain, Phenotyping, Cluster analysis, Patient-reported measures

Introduction

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Every day, health care providers face challenges treating chronic pain patients, as treatment effects for this condition are often disappointing. The "numbers needed to treat (NNT)" for commonly used analgesic drugs, such as anti-neuropathic drugs and opioids, fall within the 3 to 10 range [1]. Recognizing that, depending on the drug, 3 to 10 patients need to be treated for a 50% pain reduction to be achieved in one patient, can be disheartening, as it entails treatment failure in the remaining patients. This is especially poignant as analgesic drugs prescribed for chronic pain can have serious side effects, such as opioid dependency and substance use disorder, which has contributed to the opioid crisis we are currently facing [2]. Hence, our approach to chronic pain treatment demands a transformation, and a potential solution involves deepening our understanding of the distinct characteristics found in clinical subgroups of patients experiencing chronic pain [3,4]. The identification of such subgroups could improve pain management by allowing treatment to be tailored to the needs and characteristics of each subgroup, ultimately reducing the NNT for specific analgesic interventions. Identification of such patient subgroups should include biopsychosocial components, as chronic pain is a complex multi-faceted problem with important biological (e.g., genetics), psychological (e.g., anxiety, depression, pain catastrophizing), and social (e.g., low educational attainment, poor social support) factors all determining the experience of chronic pain. Several studies have supported the hypothesis that different subgroups of patients exist within different chronic pain populations, such as chronic low back pain [5], temporomandibular disorder [6] and fibromyalgia [7], whereas other studies have attempted to cluster patients in heterogenous chronic pain populations with a mix of painful conditions

[8–12]. The available studies highly vary in their use of clustering variables, psychometric instruments and statistical methods. Clusters were based on unidimensional variables of pain-related characteristics such as pain location [9], or used a more multidimensional approach [8,10–12]. Combining the main results of these studies, 2 to 4 reliable clusters emerge with psychiatric symptoms such as anxiety and depression, as well as the psychological construct of catastrophizing, proving most important for cluster allocation. A clear relation with the biomedical domain (including pain diagnosis) and the social domain (including lifestyle, educational level and employment) is still missing. Likewise, it remains unclear whether different subgroups respond differently to some analgesic therapies than other subgroups.

The current study aimed to identify different chronic pain subgroups, incorporating aspects from all three dimensions of the biopsychosocial model. Data were derived from validated questionnaires that were used to assess mental and social health status variables in a heterogenous patient population in a tertiary outpatient pain clinic setting. The derived subgroups were compared in terms of sociodemographic characteristics, lifestyle factors, perceived health related quality of life (HRQoL), pain diagnosis, and treatment response. A secondary aim was to alleviate the burden on patients currently tasked with completing multiple (extensive) pain questionnaires, by identifying those questions that are essential for cluster allocation, and suggesting a concise questionnaire for this purpose.

Methods

Study design

In this retrospective observational cohort study all chronic pain patients referred to the tertiary multidisciplinary outpatient pain clinic of the University Medical Center Utrecht (UMCU) between May 2018 and May 2021, and of the Erasmus Medical Center Rotterdam (EMC),

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

7

The Netherlands, between January 2017 and March 2023, were included. The Medical Research Ethics Committees of the UMCU (MEC-21/358) and of the EMC (MEC-2023-0161) both approved this study and waived the requirement to obtain informed consent. **Data collection** Data were derived from questionnaires and standard entry boxes in the electronic health records that were collected as part of routine clinical care. Patients completed online questionnaires prior to their initial visit to the outpatient pain clinic. A combination of different patient-reported measures related to pain characteristics, psychological distress and health related quality of life (HRQoL) variables were included. These are described below. **Sociodemographics** Sociodemographic variables assessed were age (years), gender, Body Mass Index (BMI; kg/m²), lifestyle behaviors (alcohol consumption, drug use, smoking), having children, employment status, educational level, marital status and major life events (presence or absence, open to patients' own definition). Pain intensity, characteristics, duration and interference Pain intensity was assessed using a 0 to 10 Numerical Rating Scale (NRS), with 0 equating to no pain and 10 to the worst imaginable pain, for the average, minimal and maximal pain intensity in the previous week. We addressed pain characteristics in the UMCU using the first two questions of the Douleur Neuropathique en 4 (DN4) questionnaire comprising seven items (i.e., burning, painful cold, electric shock, pins and needles, tingling, numbness and pruritus) with a dichotomous yes-no scale. The total sum scores ranged from 0-7, with a cut-off point of ≥ 3 suggesting

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

8

neuropathic pain [13]. The (Dutch) DN-4 has been validated in the general chronic pain population [14]. In the EMC, pain characteristics were assessed using the validated PainDetect, a 9-item self-report screening questionnaire [15]. It measures seven aspects of the quality of the pain experienced (i.e., burning, tingling, electric shocks, cold and heat hypersensitivity, numbness and pressure pain), the chronological pattern (time course), and whether or not the pain radiates. It is scored from 0 to 38, with total scores of less than 12 considered to represent nociceptive pain, 13–18 possible neuropathic pain, and scores >19 representing >90% likelihood of neuropathic pain. For pain duration, patients indicated whether their pain persisted for more or less than one year. Pain interference was assessed using the short form of Brief Pain Inventory (BPI) including seven items; general activity, mood, walking ability, normal work, relation with other people, sleep, and enjoyment of life. Each item was presented separately and was rated on a NRS scale from 0 to 10, with 0 indicating 'no interference of pain with daily functioning' and 10 'complete interference' [16,17]. Pain diagnosis Patients were diagnosed during their first visit to the outpatient pain clinic by their attending anesthesiologist-pain specialist, shortly after filling out the questionnaires. Pain diagnoses were assessed according to the International Classification of Diseases 10 registry (ICD-10) [18]. **Treatment effect** Treatment effect was assessed using the Global Perceived Effect (GPE) questionnaire. The GPE asks the patient to rate, on a 7-point Likert scale, how much their condition has

improved or deteriorated since the start of treatment [19]. In the UMCU cohort a subgroup of patients with peripheral neuropathic pain or scar pain received a high concentration capsaicin 8% skin patch. Treatment effect was measured 14 days after capsaicin treatment. In the EMC cohort, treatment effect was measured three months after treatment initiation (multidisciplinary treatment) at the tertiary pain clinic.

Psychological distress variables

Psychological distress was measured using three different questionnaires. The *Hospital Anxiety and Depression Scale (HADS)* self-assessment questionnaire assesses the level of anxiety and depression symptoms [20,21]. The *Pain Catastrophizing Scale (PCS)* assesses catastrophizing in three dimensions: magnification, rumination and helplessness [22–24]. The *Tampa Scale of Kinesiophobia (TSK)* questionnaire assesses fear of movement and injury [25].

Health-related Quality of life

In the UMCU cohort, patients completed either the European Quality of Life instrument (EQ5D) or 12-item Short Form Health Survey (SF-12), because clinical practice changed during the study period, with a switch from the EQ5D to the SF-12. In the EMC cohort, the 36-item Short Form Health Survey (SF-36) was used. Details of the abovementioned questionnaires are reported in the Supplementary file to this methods section.

Statistical analyses

A statistical analysis plan was formalized before accessing the data for the primary outcome.

No statistical power calculation was conducted prior to the study and all available data were included. Hierarchical clustering was performed on psychometric data using the individual

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

10

dichotomous variable of "improved" (including little improvement, much improvement, and


fully recovered) or "not improved" (including unchanged, little worse, much worse, and very bad) after treatment. Differences in treatment effects were analysed using a Pearsons-Chisquare test with improvement yes/no as outcome parameter, and a paired T-test for pain decrease (NRS) as outcome measure. Statistical analyses were performed using IBM SPSS Statistics version 26.0 to compare derived clusters for pain intensity, duration, characteristics and interference, pain diagnosis, sociodemographic variables, and HRQoL) and R version 4.2.2.

Results

Sample description

In total, 8,133 patients were included in the study, of whom 2,654 were referred to the UMCU and 5,479 to the EMC. Of these, 1,043 (UMCU; 39%) and 1,636 (EMC; 30%) were excluded due to one or more missing values in the questionnaires used for cluster analysis, resulting in 1,611 UMCU patients and 3,843 EMC patients in the final analysis (Fig 1).

Fig 1. Flowchart of study population



The patients in the UMCU cohort were slightly older than in the EMC cohort (mean age 54.5 years (95% CI 53.7-55.4) versus 49.9 (95% CI 49.4 -50.4)). There were fewer females included in the UMCU population (53.9% females versus 64.2% in the EMC). The majority in both cohorts was married or cohabiting (UMCU 77.3% and EMC 75.0%) and had children (UMCU 71.5% and EMC 68.2%). A minority of patients was employed (UMCU 35.8% and EMC 37.1%) (Table 1).

Table 1. Sociodemographics, pain intensity, duration, character, interference and health-related quality of life in the study population (University Medical Center Utrecht and Erasmus Medical Center Rotterdam).

Variables	Total sample	Total ample		

	UMCU (n=1,611)	EMC (n=3,855)
Age (y)	54.5 (53.7-55.4)	49.9 (49.4-50.4)
Gender (female)	829 (53.9%)	2478 (64.2%)
BMI (kg/m ²⁾	26.7 (25.9-27.5)	24.2 (23.2-25.1)
Daily smoking (yes)	269 (17.3%)	638 (23.6%)
Regular alcohol consumption	273 (17.5%)	NA
(>3 days per week yes/no)		
Drugs (used once or more,	102 (6.6%)	NA
yes/no)		
Highest educational level		
-Primary education	40 (2.9%)	318 (8.3%)
-Secondary education	578 (41.8%)	825 (21.4%)
-Vocational education	388 (27.9%)	1727 (44.9%)
-University	87 (6.3%)	897 (23.3%)
-Education not specified	291 (21.1%)	80 (2.1%)
Employment status		
-Student	38 (2.5%)	114 (4.2%)
-Retired	397 (25.7%)	468 (17.3%)
-Homemaker	49 (3.2%)	256 (9.5%)
-Volunteer	34 (2.2%)	NA
-Unemployed	462 (29.9%)	811 (30.0%)
-Employed	552 (35.8%)	1003 (37.1%)
-Other	11 (0.7%)	50 (1.8%)
Marital status		
-Single	353 (22.7%)	956 (24.9%)

-Cohabitation/marriage	1200 (77.3%)	2891 (75%)
Children (yes)	1114 (71.5%)	1842 (68.2%)
Life-changing events (yes)	830 (54.2%)	NA
Average pain (NRS)	7 (2)	8 (2)
Minimum Pain (NRS)	4 (3)	5 (4)
Maximum Pain (NRS)	9 (2)	9 (1)
Pain duration (%) ≥ 1 year	71.3%	86.4%
Neuropathy (DN4)		
Median	5 (3)	NA
Score >3 (%)	71.4%	NA
Neuropathy (PD)	NA	39.9%
>90% Certainty (%)		
Brief Pain Inventory		
General Activity	7 (3)	7 (2)
Mood	6 (4)	7 (3)
Walking ability	7 (5)	7 (5)
Normal Work	7 (3)	8 (3)
Relations with other people	5 (5)	6 (5)
Sleep	7 (4)	7 (4)
Enjoyment of life	6 (5)	7 (5)
Health-Related Quality of Life		
SF12 Physical	25.4 (24.8-26.0)	NA
SF12 Mental	42.8 (42.3-43.3)	NA
SF36 Physical	NA	31.9 (31.6-32.1)
SF36 Mental	NA	45.1 (44.8-45.4)

EQ5D-VAS (0-100)	42.8 (40.8-44.8)	NA
EQ5D Index	0.74 (0.73-0.75)	NA

253 Table 1 Legend. Sociodemographics, pain intensity, duration, character, interference and 254 health-related quality of life in the study population (University Medical Center Utrecht and 255 Erasmus Medical Center Rotterdam). 256 Data expressed as mean (95% confidence interval), median (IQR) or count (%). 257 BMI: Body Mass Index; DN4: Douleur Neuropathique en 4; EMC: Erasmus Medical Center 258 Rotterdam; EO5D: European Quality of Life instrument 5; EO5DVAS: European Quality of 259 Life instrument 5-Visual Analogue Scale; NRS: Numeric Rating Scale; PD: PainDetect; 260 SF12: Short Form-12; SF36: Short Form-36; UMCU: University Medical Center Utrecht. 261 262 In the EMC cohort, more patients had experienced pain for more than 1 year (86.4% versus 263 71.3% in the UMCU cohort), with no difference in pain intensity between the cohorts (median 264 NRS in the past week in UMCU cohort was 7 (IQR= 5-9) versus 8 (IQR= 6-10) in the EMC). 265 We cannot meaningfully compare presence of neuropathic pain characteristics between both 266 cohorts as two different questionnaires (DN4 and PainDetect) were used (Table 1). In the 267 UMCU cohort, the most common diagnoses were radicular syndrome (24.7%), mechanical 268 spine related pain (11.6%), and mononeuropathy (8.1%) (Table 2). In the EMC, this was

Table 2. Frequencies of the 10 most common diagnoses in each cluster for the <u>discovery</u>

"other neuropathic pain" (17.5%), radicular syndrome (17.0%) and tendomyogenic pain

273 <u>cohort (UMCU)</u>

(12.1%) (S1 Table).

269

270

271

	Total	Cluster 1	Cluster 2	Cluster 3	X^2 (df)	p-value
Top 10 Diagnoses (%)					79.1 (62)	0.070


1. Radicular syndrome	24.7%	17.1%	26.5%	24.6%
2. Mechanical spine related pain	11.6%	11.0%	10.5%	13.2%
3. Mononeuropathy	8.1%	8.8%	8.8%	7.1%
4. Joint pain	7.3%	8.3%	7.4%	6.9%
5. Polyneuropathy	5.7%	6.6%	4.8%	6.4%
6. Post-surgical pain	5.6%	5.5%	5.2%	6.1%
7. Orofacial pain	4.4%	3.9%	4.3%	4.7%
8. Abdominal pain	4.2%	3.3%	4.8%	3.7%
9. Myofascial pain	4.2%	5.0%	4.5%	3.7%
10. Widespread pain	2.4%	6.1%	2.0%	1.8%

Table 2 Legend. Frequencies of the 10 most common diagnoses in each cluster for the discovery cohort (UMCU). Data expressed as percentage per cluster. Significance levels computed by Pearson-Chi square. There is no missing data.

Hierarchical clustering revealed 3 clusters of patients.

We first performed a hierarchical clustering on the combined datasets (UMCU and EMC) using the individual questions of the HADS-A, HADS-D, PCS and TSK questionnaires. We identified 3 distinct clusters of patients: Cluster 1 included 750 patients (13.8%), Cluster 2 1,795 patients (32.9%), and Cluster 3 comprised of 2,909 patients (53.3%) (Fig 2). When performing separate hierarchical clustering on the datasets (i.e., UMCU data separate from EMC data), we found that more than 75% of the patients were assigned to the same cluster (not shown).

Fig 2. Hierarchical clustering dendogram of the cohorts combined (UMCU and EMC).



Hierarchical cluster analysis showing three clusters: Cluster 1(red), Cluster 2 (blue) and Cluster 3 (green). X-axis representing the individual questions of three questionnaires (Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and Tampa Scale of Kinesiophobia (TSK). Y-axis representing included patients.

Cluster 1 was characterized by higher scores for anxiety (HADS-A mean 13.4; 95%CI=13.1-13.7), depression (HADS-D mean 13.6 (95%CI=13.3-13.9)), catastrophizing (PCS mean 43.6; 95%CI=43.2-44.0) and kinesiophobia or pain related fear (TSK mean 46.9; 95%CI=46.4-47.4). Cluster 2 on the other hand was characterized by the lowest scores for each of these characteristics (HADS-A mean 3.7; 95%CI=3.6-3.8, HADS-D mean 4.1; 95%CI=4.0-4.3, PCS mean 10.3; 95%CI=10.0-10.6 and TSK 34.0; 95%CI=33.7-34.3), while cluster 3 showed intermediate scores, at or just passing the cut-off scores for anxiety, depression,

 $303 \quad 8.0, \ \ PCS \quad 26.8; \quad 95\%CI = 26.5 - 27.1 \quad and \quad TSK \quad 40.1; \quad 95\%CI = 39.9 - 40.4) \quad (Table \quad 3).$

Table 3. Clustering characteristics in the total study population (UMCU and EMC) and comparison among the clusters.

Variables	Total sample	Cluster 1	Cluster 2	Cluster 3	<i>p</i> -value	Effect size
	(n=5454)	(n=750, 13.8%)	(n=1795, 32.9%)	(n=2909, 53.3 %)		Eta-squared
Anxiety (HADS-A)	6.8 (6.7-7.0)	13.4 (13.1-13.7)	3.7 (3.6-3.8)	7.1 (6.9-7.2)	<0.001	0.455
-Signs of anxiety	30.6%	87.3%	3.7%	32.7%		
disorder (Score >8 (%))						
-Clinical significant	20.4%	78.3%	1.0%	17.4%		
anxiety disorder (Score						
>10 (%))						
Depression (HADS-D)	7.4 (7.3-7.6)	13.6 (13.3-13.9)	4.1 (4.0-4.3)	7.9 (7.7-8.0)	<0.001	0.373
-Signs of depression	39.3%	89.5%	11.8%	43.4%		
(Score >8 (%))						
-Clinical significant	27.4%	78.3%	5.0%	28.2%		
depression (Score >10						
(%))						

Pain catastrophizing	23.7 (23.3-24.0)	43.6 (43.2-44.0)	10.3 (10.0-10.6)	26.8 (26.5-27.1)	<0.001	0.703
(PCS) Total score						
Rumination	8.8 (8.7-9.0)	14.5 (14.4-14.6)	4.5 (4.3-4.6)	10.1 (10.0-10.2)		
Magnification	3.4 (3.3-3.4)	8.5 (8.3-8.7)	0.9 (0.8-0.9)	3.6 (3.5-3.7)		
Helplessness	11.5 (11.3-11.6)	20.6 (20.4-20.8)	5.0 (4.8-5.1)	13.1 (13.0-13.3)		
Pain-related fear (TSK)	39.0 (38.8-39.2)	46.9 (46.4-47.4)	34.0 (33.7-34.3)	40.1 (39.9-40.4)	<0.001	0.273

305 *Table 3 Legend.* Clustering characteristics in the total study population (UMCU and EMC) and comparison among the clusters.

306 Data expressed as mean (95% confidence interval) or percentage (%) of count data. Statistics computed by one-way ANOVA and effect sizes are

calculated with eta squared with < 0.06 as small, 0.06 to 0.14 as medium and ≥ 0.14 as a larger effect size,

308 EMC: Erasmus Medical Center Rotterdam; HADS-A and HADS-D: Hospital Anxiety and Depression Scale; PCS: Pain Catastrophizing Scale;

TSK: Tampa Scale for Kinesiophobia; UMCU: University Medical Center Utrecht.

PCS subcategories represent the sum of following items 'Rumination' 8,9, 10 and 11; Magnification 6, 7 and 13; 'Helplessness' 1, 2, 3, 4, 5 and

12. Percentage of missing data: HADS 0%, PCA 0%, TSK 0%

307

309

311

312

315

316

317

318

319

320

321

322

323

324

325

326

21

Regarding sociodemographic characteristics and lifestyle behaviors, patients in cluster 1

smoked tobacco more often, and were more often single. Patients in cluster 2 consumed more

alcohol (in UMCU cohort; this was not recorded in the EMC cohort), had the highest

educational levels, and the highest employment rates (Table 4, and S2 Table).

Variables	Total sample	Cluster 1	Cluster 2	Cluster 3	$\chi^2(df)$	<i>p</i> -value	Effect size
	(n=1,611)	(n=181, 11.2%)	(n=807, 50.1%)	(n=623, 38.7%)			
Age (y)	54.5 (53.7-55.4)	53.7 (51.3-56.1)	54.7 (53.5-55.9)	54.6 (53.2-56.0)		0.776	
Gender (female)	829 (53.9%)	50%	56.1%	52.3%		0.202	
BMI (kg/m ²⁾	26.7 (25.9-27.5)	26.9 (25.5-28.3)	27.1 (25.6-28.5)	26.2 (25.4-27.0)		0.578	
Daily smoking (yes)	269 (17.3%)	26.0%	11.8%	21.8%	34.5 (2)	< 0.001	0.149
Regular alcohol	273 (17.5%)	9.0%	20.9%	15.7%	16.4 (2)	< 0.001	0.103
consumption (>3 days							
per week yes/no)							
Drugs (used once or	102 (6.6%)	7.3%	5.5%	7.7%	2.8 (2)	0.250	
more, yes/no)							
Highest educational level					108.5 (8)	< 0.001	0.198
-Primary education	40 (2.9%)	13.5%	0.9%	2.2%			

578 (41.8%)	47.2%	36.0%	47.4%			
388 (27.9%)	24.5%	29.7%	26.8%			
87 (6.3%)	5.0%	7.9%	4.7%			
291 (21.1%)	9.8%	25.5%	18.9%			
				136.9 (18)	< 0.001	0.211
38 (2.5%)	1.1%	2.6%	2.7%			
397 (25.7%)	25.3%	26.9%	24.3%			
49 (3.2%)	4.0%	2.1%	4.4%			
34 (2.2%)	2.9%	1.9%	2.4%			
62 (29.9%)	48.9%	21.4%	35.6%			
552 (35.8%)	14.9%	44.7%	30.2%			
11 (0.7%)	2.9%	0.4%	0.5%			
				15.7 (2)	< 0.001	0.101
353 (22.7%)	33.3%	19.7%	23.6%			
200 (77.3%)	66.6%	80.3%	76.4%			
114 (71.5%)	73.4%	70.6%	72.2%	0.7 (2)	0.690	
3	88 (27.9%) 87 (6.3%) 91 (21.1%) 38 (2.5%) 97 (25.7%) 49 (3.2%) 34 (2.2%) 62 (29.9%) 52 (35.8%) 11 (0.7%) 53 (22.7%) 200 (77.3%)	88 (27.9%) 24.5% 87 (6.3%) 5.0% 91 (21.1%) 9.8% 38 (2.5%) 1.1% 97 (25.7%) 25.3% 49 (3.2%) 4.0% 34 (2.2%) 2.9% 62 (29.9%) 48.9% 52 (35.8%) 14.9% 11 (0.7%) 2.9% 53 (22.7%) 33.3% 200 (77.3%) 66.6%	88 (27.9%) 24.5% 29.7% 87 (6.3%) 5.0% 7.9% 91 (21.1%) 9.8% 25.5% 38 (2.5%) 1.1% 2.6% 97 (25.7%) 25.3% 26.9% 49 (3.2%) 4.0% 2.1% 34 (2.2%) 2.9% 1.9% 62 (29.9%) 48.9% 21.4% 52 (35.8%) 14.9% 44.7% 11 (0.7%) 2.9% 0.4% 53 (22.7%) 33.3% 19.7% 200 (77.3%) 66.6% 80.3%	88 (27.9%) 24.5% 29.7% 26.8% 87 (6.3%) 5.0% 7.9% 4.7% 91 (21.1%) 9.8% 25.5% 18.9% 38 (2.5%) 1.1% 2.6% 2.7% 97 (25.7%) 25.3% 26.9% 24.3% 49 (3.2%) 4.0% 2.1% 4.4% 34 (2.2%) 2.9% 1.9% 2.4% 62 (29.9%) 48.9% 21.4% 35.6% 52 (35.8%) 14.9% 44.7% 30.2% 11 (0.7%) 2.9% 0.4% 0.5% 53 (22.7%) 33.3% 19.7% 23.6% 200 (77.3%) 66.6% 80.3% 76.4%	88 (27.9%) 24.5% 29.7% 26.8% 87 (6.3%) 5.0% 7.9% 4.7% 91 (21.1%) 9.8% 25.5% 18.9% 38 (2.5%) 1.1% 2.6% 2.7% 97 (25.7%) 25.3% 26.9% 24.3% 49 (3.2%) 4.0% 2.1% 4.4% 34 (2.2%) 2.9% 1.9% 2.4% 62 (29.9%) 48.9% 21.4% 35.6% 52 (35.8%) 14.9% 44.7% 30.2% 11 (0.7%) 2.9% 0.4% 0.5% 15.7 (2) 53 (22.7%) 33.3% 19.7% 23.6% 200 (77.3%) 66.6% 80.3% 76.4%	88 (27.9%) 24.5% 29.7% 26.8% 87 (6.3%) 5.0% 7.9% 4.7% 91 (21.1%) 9.8% 25.5% 18.9% 136.9 (18) <0.001

Life-changing events	830 (54.2%)	50.9%	58.3%	49.9%	10.4 (2)	0.006	0.006
(yes)							
Average pain (NRS)	7 (2)	9 (1)	7 (2)	8 (1)	236.3 (20)	< 0.001	0.275
Minimum Pain (NRS)	4 (3)	6 (3)	4 (3)	5 (3)	201.4 (20)	< 0.001	0.254
Maximum Pain (NRS)	9 (2)	10(1)	8 (1)	9 (2)	184.3 (20)	< 0.001	0.243
Pain duration (%) ≥ 1							
year	71.3%	76.8%	67.8%	74.1%	8.3 (2)	0.015	0.079
Neuropathy (DN-4)							
Total score	5 (3)	5 (3)	3 (3)	4 (3)	70.0 (20)	< 0.001	0.150
Score >3 (%)	71.4%	83.6%	67.3%	73.2%			
Brief Pain Inventory							
General Activity	7 (3)	8 (2)	6 (3)	7 (2)	258.7 (20)	< 0.001	0.288
Mood	6 (4)	8 (2)	5 (4)	7 (3)	441.3 (20)	<0.001	0.376
Walking ability	7 (5)	8 (2)	5 (6)	7 (3)	167.7 (20)	< 0.001	0.232
Normal Work	7 (3)	9 (2)	7 (4)	8 (2)	239.6 (20)	< 0.001	0.277
Relations with other	5 (5)	8 (3)	3 (6)	6 (4)	321.7 (20)	<0.001	0.321

people							
Sleep	7 (4)	8 (3)	6 (5)	7 (3)	189.7 (20)	< 0.001	0.247
Enjoyment of life	6 (5)	8 (3)	5 (5)	7 (3)	415.2 (20)	<0.001	0.365
Health-Related Quality							
of life							
SF12 Physical	25.4 (24.8-26.0)	20.6 (19.2-22.0)	27.9 (27.0-28.8)	23.3 (22.5-24.1)		<0.001	0.089
SF12 Mental	42.8 (42.3-43.3)	39.2 (38.0-40.4)	44.1 (43.4-44.8)	42.0 (41.2-42.7)		< 0.001	0.048
EQ5D-VAS (0-100)	42.8 (40.8-44.8)	29.5 (23.5-35.6)	49.0 (46.2-51.8)	39.0 (36.0-42.1)		<0.001	0.070
EQ5D Index	0.74 (0.73-0.75)	0.64 (0.63-0.66)	0.78 (0.78-0.79)	0.72 (0.71-0.73)		<0.001	0.334

Table 4 Legend. Sociodemographics, pain intensity, duration, character, interference and health-related quality of life in the discovery cohort

(UMCU) and comparison among the clusters.

Sociodemographic data expressed as mean (95% confidence interval) or count (%). Questionnaire scores are expressed as median (interquartile
range) or count (%). Statistics computed by one-Way ANOVA Test or Pearson Chi-Square test. Effect sizes for continuous data were estimated
using eta squared with <0.06 as small, 0.06 to 0.14 as medium and ≥0.14 as a larger effect size. Effect sizes for categorical data are calculated
with Cramer's V. Significance levels computed by Pearson Chi-Square test and effect sizes with Cramer's V indicating small 0.1 to 0.3, medium

0.3 to 0.5 and large >0.5 effect sizes. Significant differences with medium to large effect size are in bold.

Percentage of missing data: age 0.3%, gender 4.6%, BMI 76.0%, daily smoking 3.4%, regular alcohol 3.4%, drugs 3.4%, highest educational level 14.3%, employment status 4.3%, marital status 3.7%, children 3.4%, life-changing events 5.1%, pain NRS 0.2%, DN4 0,2%, BPI items 0.2%, TSK, HADS 0.3%, PCS 0.2%, SF12 43.8%, EQ5D 59.5%.

BMI: Body Mass Index; DN4: Douleur Neuropathique en 4; EQ5D: European Quality of Life instrument 5; EQ5D`-VAS: European Quality of Life instrument 5-Visual Analogue Scale; NRS: Numeric Rating Scale; SF12: Short Form-12; UMCU: University Medical Center Utrecht.

339

In the UMCU cohort, pain was most severe in cluster 1 with the highest intensity (median pain during the past week NRS 9; IQR= 8-10), longest 341 342 duration (76.8% over one year) and highest prevalence of neuropath (83.6%). Cluster 2 showed lowest pain severity scores (NRS 7; IQR=5-9, pain duration > 1 year in 67.8% of patients, 67.3% show signs of neuropathy) and cluster 3 intermediate scores (NRS 8; IQR=7-9, pain duration 343 344 > 1 year in 74.1% of patients, 73.2% signs of neuropathy). Differences were significant between groups (Table 4). 345 In the EMC cohort, some different observations were made. Pain intensity and duration were comparable between clusters. Signs of neuropathic 346 pain however were most often observed in cluster 2 (50.8%), compared with 31.9% in cluster 1 and 39.5% in cluster 3. All differences had a small effect size (S2 Table). 347 In cluster 1, widespread pain (UMCU cohort) and tendomyogenic pain (EMC cohort) were most prevalent, and radicular syndrome least 348 349 prevalent (both cohorts). Complex regional pain syndrome (EMC cohort) was most prevalent in cluster 2. For all other diagnoses, there were no clinically relevant differences in prevalence among clusters (Table 2, S1 Table). Pain influenced HRQoL most in cluster 1 in both cohorts (Table 350 4, S2 Table). 351

Treatment efficacy differs between clusters

352

353

354

355

356

Next, we tested whether medical treatment efficacy was different between the three subgroups. In n=104 patients referred to the UMCU and receiving a Capsaicin 8% patch for peripheral neuropathic pain or scar pain, 28.6% of those in cluster 1 experienced improvement at 14 days follow up after treatment, compared to , 58.9% and 55.9% in cluster 2 and 3 respectively. In cluster 1, although patients reported a small

improvement on the GPE, maximum pain scores did not decrease significantly (NRS mean 8.9 (95%CI=8.4-9.5) to 8.6 (95%CI=8.0-9.3), p=0.391) at 14 days follow-up, while in cluster 2 and 3 a significant reduction in maximum pain scores was observed (cluster 2 NRS mean 8.1 (95%CI=7.8-8.4) to 6.2 (95%CI=5.5-6.9), p<0.001; cluster 3 NRS mean 8.2 (95%CI=7.8-8.5) to 6.5 (95%CI=5.7-7.3), p<0.001) (Table 5).

Treatment outcome was assessed three months after baseline in n=497 (12.9%) patients who were referred to the EMC and received multidisciplinary pain treatment (all treatment options in the EMC are included). Improvement was reported in 18.2% of patients in cluster 1, compared to 51.0% in cluster 2, and 51.5% in cluster 3 (Table 5).

Table 5. Treatment

cluster

effect differs between

	Cluster 1	Cluster 2	Cluster 3	Pearson Chi Square p-value	Cramer\$65
UMCU – Capsaicin 8% patch	N=14	N=56	N=34		366
GPE improved	4 (28.6%)	33 (58.9%)	19 (55.9%)	Cluster 1 vs 2	367
				p=0.119	307
				Cluster 1 vs 3	
				p=0.267	
				Cluster 2 vs 3	
				p=0.992	
Max NRS before treatment (mean)	8.9 (8.4-	8.1 (7.8-	8.2 (7.8-	NA	
	9.5)	8.4)	8.5)		
Max NRS after treatment (mean)	8.6 (8.0-	6.2 (5.5-	6.5 (5.7-	NA	
	9.3)	6.9)	7.3)		
Paired t-test	0.391	< 0.001	< 0.001		
EMC-multidisciplinairy pain	N=11	N=257	N=229		
treatment					
GPE improved	2 (18.2%)	131	118	Cluster 1 vs 2	0.130
		(51.0%)	(51.5%)	p=0.033	0.139
				Cluster 1 vs 3	

	p=0.031	368	30	medRxiv preprint (which was i
	Cluster 2 vs 3 p=0.903	369		t doi: htt not cer
				medRxiv preprint doi: https://doi.org/10.1101/2024.02.23.24302234; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 5 Legend. Treatment effect differs between cluster 370 371 Treatment effect (global perceived effect and pain numeric rating scale) were assessed two weeks after application of a capsaicin 8% patch in 372 patients with peripheral neuropathic pain or scar pain in a subgroup of patient in the UMCU cohort. Treatment effect (global perceived effect) 373 was assessed three months after baseline after a multidisciplinary treatment in the EMC cohort. All available data was used. The global perceived effect was categorized to "improved" of "not improved (including no change)". Data expressed as count (%). Significance 374 levels computed by Pearson Chi-Square test and effect sizes with Cramer's V indicating small 0.1 to 0.3, medium 0.3 to 0.5 and large >0.5 effect 375 376 sizes. 377 The pain numeric rating scale was calculated as mean and baseline and follow up NRS scores were calculated within clusters using a paired-378 *sample t-test. P-values* < 0.05 *were regarded as significant.*

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

In a post-hoc analysis, we next aimed to predict cluster membership by using the UMCU dataset as a discovery cohort and the EMC dataset as a validation cohort. Each patient (from the discovery and validation cohort) was assigned to the cluster defined in the analysis pooling both datasets together. We used a random forest approach to classify the patients of the discovery cohort and reached an overall accuracy of 86%, with overall high sensitivity and specificity for each cluster (S3A Table). The defined prediction model was then used on the validation cohort and the predicted memberships were compared to the ones assigned by the previously performed hierarchical clustering. When using all the questions (n=44), the accuracy was 72.6% and cluster specific sensitivity and specificity were high for cluster 1 and 2 (S3A Table). To reduce patients' burden in having to answer multiple lengthy questionnaires, we next investigated whether we could reduce the number of questions and still obtain adequate accuracy, sensitivity and specificity for the prediction model. An advantage of a random forest model is that it tells one which variables are most important to accurately predict classes. Hence, we again used the validation cohort, but this time with only the 20 most important questions (S1 Fig). This new model showed an accuracy of 70.3%, again with good sensitivity and specificity (S3B Table). Using the 15 most important questions resulted in an accuracy of 70.0% (S3C Table), while using the 10 most important questions yielded an accuracy of 69.6% but lower balanced accuracy (S3D Table). Overall, using the 15 most important questions seems to provide the best balance between number of questions and desired prediction accuracy. The balanced accuracy with 15 questions for clusters 1, 2 and 3 was 91%, 84% and 68% respectively. The prediction model has an approximate sensitivity for cluster 1, 2 and 3 of 96%, 74% and 58%, and specificity of 86%, 95% and 77%, respectively.

The top three most important questions for cluster allocation were 1. "I still enjoy the things I used to enjoy", 2 "Worrying thoughts go through my mind", and 3. When I'm in pain it's awful and I feel that it overwhelms me."

Discussion

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

Treatment failure in chronic pain patients is very common. Our aim was to identify subgroups of patients that are more or less likely to respond to certain interventions, so we can tailor subgroup-specific treatments to improve pain management. Based on the HADS, PCS and TSK questionnaires, we identified three chronic pain subgroups in a heterogeneous patient population (n=5,454) in two tertiary outpatient settings using hierarchical cluster analysis. Cluster 1 was characterized by high psychological burden, more tobacco smoking, lower educational levels, lower employment rates and more singles. Cluster 2 showed low psychological burden, more alcohol consumption, higher educational levels and higher employment rates. Cluster 3 showed intermediate features compared to the other clusters. Pain intensity and pain characteristics did not differ appreciably between the clusters in both cohorts. Regarding pain diagnosis, in cluster 1 widespread pain (UMCU cohort) and tendomyogenic pain (EMC cohort) were most prevalent. We hypothesize that patients with these diagnoses belong to a comparable diagnosis group with multifocal poorly defined chronic pain and that due to challenges in the classification of this pain syndrome this was either classified as widespread pain or tendomyogenic pain in the two centers. Complex regional pain syndrome (EMC cohort) was most prevalent in cluster 2. For all other diagnoses, there were no clinically relevant differences in prevalence among clusters. Importantly, treatment success was comparable between clusters 2 and 3, but was consistently and significantly lower in cluster 1. We hypothesize that patients identified as belonging to cluster 1 may need a different treatment approach, with suggestions provided below.

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

34

When comparing our findings with the current literature on cluster analyses of populations with chronic pain, the majority of studies also report differences observed in the psychological domain. Some of these studies found similar 'extreme' groups regarding psychological characteristics and pain experience, similar to our clusters 1 and 2, along with one or more intermediate group(s) like our cluster 3 [5,7-12,26]. The number of clusters differs between studies, varying from 2 to 9 clusters. Discrepancies in the number of clusters between different studies might be due to differences in the study populations or clustering variables used as input variables. Our identification of three clusters in a heterogenous chronic pain population (in the combined dataset and in both cohorts separately; see S2A and S2B Fig) is consistent with the findings of Gerdle et al. [12] and Gilam et al[26]. Gerdle et al. identified three groups based on variables of pain intensity, emotional distress, acceptance and life impacts. Their study revealed a group with overall 'worst' characteristics that included fewer subjects with a university education, similar to our cluster 1; a contrasting group with 'best' characteristics and with the highest proportion of subjects with university education, similar to our cluster 2, and an intermediate group similar to our cluster 3. Gilam et al. identified three groups based on three domains: physical, mental and social. In line with our clusters, the three groups showed graded severity in all of these domains and associated pain characteristics. Moreover, mental symptoms of anxiety, depression and anger were found to be the key determinants of subgroup assignment. Similarly, in our study, anxiety and depression belonged to the variables with the highest determinant value between all groups. Some studies added pain diagnoses in the clustering analysis. In contrast to our study, Bäckryd et al. [10] identified four subgroups and found an asymmetrical distribution of different diagnoses across groups, although these differences were small. Reviewing all these studies and including the observations in our own two large cohorts, we conclude that

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

35

pain can lead to a decreased HRQoL [34]. It is therefore not surprising that the identified

groups showed such a pattern and that two groups (cluster 1 and cluster 2) emerged with highly contrasting characteristics.

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

In the current study the prevalence of most pain diagnoses did not differ between the three clusters, and the difference in pain intensity and characteristics between clusters were small and only significant in one of our two cohorts. This suggests that the actual initial inciting stimulus or painful condition may be of lesser importance to the chronic pain experience (duration, impact and severity) than psychosocial factors are. While the psychosocial factors may not be exclusive or specific for chronic pain, pain treatment outcomes were significantly different between cluster 1 and the other two clusters. This suggests that patients from cluster 1 present with a unique set of psychosocial factors that may need a different treatment approach. Possible changes in pain management could include pain education tailored to the educational level of the patient to improve understanding of their disease, lifestyle coaching including cessation of smoking (which is associated with higher pain intensity, pain interference and pain-related fear [35]), and support by social workers in finding a job and improving socioeconomic status to reduce stress that is associated with worse chronic pain. Naturally, patients with signs of a clinically significant anxiety or depressive disorder should be referred for psychiatric care, but we want to emphasize that this alone might not be enough, as the multidisciplinary treatment offered at the EMC (and also UMCU) included psychological and/or psychiatric referral when indicated.

There were three diagnoses: widespread pain, tendomyogenic pain and CRPS, which were not equally distributed across the clusters. Tendomyogenic pain and widespread pain are known to be associated with depression [36], which may explain the higher prevalence in cluster 1. CRPS is more often diagnosed in women which provides an explanation for the sex difference

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

37 observed between both cohorts. In cluster 2, CRPS was overrepresented, for which no clear underlying cause could be identified. This overrepresentation warrant further investigation into possible underlying factors or covariates within this specific cluster (e.g. lifestyle factors, educational level influencing coping strategy). The differences in the overall diagnosis distribution between the two centers seem mainly related to differences in research focus and healthcare expertise; the EMC is an expertise centre for CRPS, explaining the larger number of CRPS patients in their cohort. This study has several strengths, including a large heterogenous chronic pain sample included at two multidisciplinary tertiary pain centres, with variables representing the different potential drivers of chronic pain according to the biopsychosocial model. However, this study also has several limitations that must be considered. First, approximately one third of patients had to be excluded from the hierarchical cluster analysis due to one or more missing values in the questionnaires. This large proportion of missing data might have biased the results, when patients not willing or not able to fill out all the questions are overrepresented in the excluded group. Second, the present results are based on a group of patients referred to a tertiary academic pain clinic, which tend to represent the most complex cases. Therefore, our findings may not generalize to other chronic pain populations and should be verified across different chronic pain patients and in different clinical settings. Third, due to the cross-sectional design

may be more successful in manipulating their answers to questionnaires (such as the HADS, PCS and TCK) to reduce their psychological burden result and prevent a possible referral to the psychiatrist or psychologist when the patient is not motivated or open to such intervention.

of this study, causality cannot be determined. Lastly, the results are based on self-reported

outcomes and could be biased by social desirability. People with higher educational levels

Regarding clinical implications, the present study underlines the importance of acknowledging that the chronic pain population is not a homogenous group, and indicates that therapeutic interventions should be adjusted to individual patient characteristics rather than only to pain diagnoses. Subgroup assignment through psychometric questionnaires can potentially help support clinical decision making by clinicians: Using the knowledge of subgroup patterns, it can be decided which treatment options are most likely to be successful and therefore would be more preferable for the individual patient. It seems particularly important to identify patients that belong to cluster 1, as patients with this subset of characteristics are likely at risk of high-impact chronic pain, which is associated with the most suffering, most unfavourable health outcomes, increased medical costs and increased opioid use and dosage [37,38]. With our prediction model we can reliably predict cluster 1 allocation with an optimal number of questions of 15, leading to an accuracy for cluster 1 of 91% with a sensitivity of 96% and specificity of 86%. In future trials, the clinical relevance and treatment responses of subgroup-specific pain management approaches must be further evaluated.

Conclusion

In conclusion, using hierarchical cluster analysis on two population cohorts, this study identified three chronic pain subgroups with different psychological and sociodemographic characteristics based on patient-reported measures. Remarkably, these groups were largely unrelated to specific pain diagnoses. This knowledge can be potentially useful for tailoring subgroup specific treatment plans to improve chronic pain management for individual patients. Using our prediction model including 15 questions only, we can reliably predict cluster allocation, especially to cluster 1, identifying patients who need a biopsychosocial approach with tailored pain education. It would be useful to validate these results in different pain populations and clinical settings, to determine whether these subgroups are widely

clinically relevant, and to compare subgroup responses to different pain management strategies.

Acknowledgments

554

555

556

557

558

559

560

561

562

563

577

We want to thank Ilona van Gent-Bijen, George Groeneweg, and Max Brenninkmeijer for their support with the data extraction; Pain clinic secretaries for providing technical support to patients when filling out the digital questionnaires; Patients for their efforts filling in the questionnaires.

References

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. 564 [1] 565 Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-566 analysis. Lancet Neurol 2015. https://doi.org/10.1016/S1474-4422(14)70251-0. 567 [2] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic 568 pain-United States, 2016. JAMA - Journal of the American Medical Association 569 2016;315:1624–45. https://doi.org/10.1001/jama.2016.1464. 570 [3] Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and 571 new advances. The Lancet 2021;397:2082–97. https://doi.org/10.1016/S0140-572 6736(21)00393-7. 573 [4] Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, et al. Patient 574 phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. 575 576 [5] Langenmaier A-M, Amelung VE, Karst M, Krauth C, Püschner F, Urbanski D, et al.

Subgroups in chronic low back pain patients - a step toward cluster-based, tailored

578		treatment in inpatient standard care: On the need for precise targeting of treatment for
579		chronic low back pain. Ger Med Sci 2019;17:Doc09. https://doi.org/10.3205/000275.
580	[6]	Bair E, Gaynor S, Slade GD, Ohrbach R, Fillingim RB, Greenspan JD, et al.
581		Identification of clusters of individuals relevant to temporomandibular disorders and
582		other chronic pain conditions: the OPPERA study. Pain 2016;157:1266–78.
583		https://doi.org/10.1097/j.pain.000000000000518.
584	[7]	Estévez-López F, Segura-Jiménez V, Álvarez-Gallardo IC, Borges-Cosic M, Pulido-
585		Martos M, Carbonell-Baeza A, et al. Adaptation profiles comprising objective and
586		subjective measures in fibromyalgia: the al-Ándalus project. Rheumatology (Oxford)
587		2017;56:2015–24. https://doi.org/10.1093/rheumatology/kex302.
588	[8]	Larsson B, Gerdle B, Bernfort L, Levin L-Å, Dragioti E. Distinctive subgroups derived
589		by cluster analysis based on pain and psychological symptoms in Swedish older adults
590		with chronic pain - a population study (PainS65+). BMC Geriatr 2017;17:200.
591		https://doi.org/10.1186/s12877-017-0591-4.
592	[9]	Alter BJ, Anderson NP, Gillman AG, Yin Q, Jeong J-H, Wasan AD. Hierarchical
593		clustering by patient-reported pain distribution alone identifies distinct chronic pain
594		subgroups differing by pain intensity, quality, and clinical outcomes. PLoS One
595		2021;16:e0254862. https://doi.org/10.1371/journal.pone.0254862.
596	[10]	Bäckryd E, Persson E, Larsson A, one MF-P, 2018 undefined. Chronic pain patients
597		can be classified into four groups: Clustering-based discriminant analysis of
598		psychometric data from 4665 patients referred to a. JournalsPlosOrg 2018:1–19.
599	[11]	Strigo IA, Simmons AN, Giebler J, Schilling JM, Moeller-Bertram T. Unsupervised
600		learning for prognostic validity in patients with chronic pain in transdisciplinary pain
601		care. Sci Rep 2023;13:7581. https://doi.org/10.1038/s41598-023-34611-z.

602	[12]	Gerdle B, Åkerblom S, Stålnacke BM, Brodda Jansen G, Enthoven P, Ernberg M, et al.
603		The importance of emotional distress, cognitive behavioural factors and pain for life
604		impact at baseline and for outcomes after rehabilitation - A SQRP study of more than
605		20,000 chronic pain patients. Scand J Pain 2019;19:693-711.
606		https://doi.org/10.1515/sjpain-2019-0016.
607	[13]	Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison
608		of pain syndromes associated with nervous or somatic lesions and development of a
609		new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29–36.
610		https://doi.org/10.1016/j.pain.2004.12.010.
611	[14]	van Seventer R, Vos C, Giezeman M, Meerding W-J, Arnould B, Regnault A, et al.
612		Validation of the Dutch Version of the DN4 Diagnostic Questionnaire for Neuropathic
613		Pain. Pain Practice 2013;13:390–8. https://doi.org/10.1111/papr.12006.
614	[15]	Freynhagen R, Baron R, Gockel U, Tölle TR. pain <i>DETECT</i> □: a new screening
615		questionnaire to identify neuropathic components in patients with back pain. Curr Med
616		Res Opin 2006;22:1911–20. https://doi.org/10.1185/030079906X132488.
617	[16]	Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for
618		chronic nonmalignant pain. J Pain 2004;5:133-7.
619		https://doi.org/10.1016/j.jpain.2003.12.005.
620	[17]	Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann
621		Acad Med Singap 1994;23:129–38.
622	[18]	World Health Organization. ICD-10□: international statistical classification of diseases
623		and related health problems □: tenth revision, 2nd ed. 2004.
624	[19]	Hudak PL, Wright JG. The characteristics of patient satisfaction measures. Spine (Phila
625		Pa 1976) 2000;25:3167–77. https://doi.org/10.1097/00007632-200012150-00012.

626	[20]	LoMartire R, Äng BO, Gerdle B, Vixner L. Psychometric properties of Short Form-36
627		Health Survey, EuroQol 5-dimensions, and Hospital Anxiety and Depression Scale in
628		patients with chronic pain. Pain 2020;161:83-95.
629		https://doi.org/10.1097/j.pain.000000000001700.
630	[21]	Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr
631		Scand 1983;67:361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x.
632	[22]	Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure,
633		reliability, and validity of the Pain Catastrophizing Scale. J Behav Med 1997;20:589-
634		605. https://doi.org/10.1023/A:1025570508954.
635	[23]	van Damme S, Crombez G, Bijttebier P, Goubert L, van Houdenhove B. A
636		confirmatory factor analysis of the Pain Catastrophizing Scale: invariant factor
637		structure across clinical and non-clinical populations. Pain 2002;96:319-24.
638		https://doi.org/10.1016/S0304-3959(01)00463-8.
639	[24]	Sullivan MJL BSPJ. The Pain Catastrophizing Scale: Development and validation.
640		Psychol Assess 1995;7:524–32.
641	[25]	Vlaeyen JWS, Kole-Snijders AMJ, Boeren RGB, van Eek H. Fear of
642		movement/(re)injury in chronic low back pain and its relation to behavioral
643		performance. Pain 1995;62:363–72. https://doi.org/10.1016/0304-3959(94)00279-N.
644	[26]	Gilam G, Cramer EM, Webber KA, Ziadni MS, Kao M-C, Mackey SC. Classifying
645		chronic pain using multidimensional pain-agnostic symptom assessments and
646		clustering analysis. Sci Adv 2021;7. https://doi.org/10.1126/sciadv.abj0320.
647	[27]	McKee-Ryan F, Song Z, Wanberg CR, Kinicki AJ. Psychological and Physical Well-
648		Being During Unemployment: A Meta-Analytic Study. Journal of Applied Psychology
649		2005;90:53-76. https://doi.org/10.1037/0021-9010.90.1.53.

650	[28]	Paul KI, Moser K. Unemployment impairs mental health: Meta-analyses. J Vocat
651		Behav 2009;74:264–82. https://doi.org/10.1016/j.jvb.2009.01.001.
652	[29]	Latza U, Kohlmann T, Deck R, Raspe H. Influence of Occupational Factors on the
653		Relation Between Socioeconomic Status and Self-Reported Back Pain in a Population-
654		Based Sample of German Adults With Back Pain. Spine (Phila Pa 1976)
655		2000;25:1390-7. https://doi.org/10.1097/00007632-200006010-00011.
656	[30]	Mackey LM, Blake C, Casey M-B, Power CK, Victory R, Hearty C, et al. The impact
657		of health literacy on health outcomes in individuals with chronic pain: a cross-sectional
658		study. Physiotherapy 2019;105:346–53. https://doi.org/10.1016/j.physio.2018.11.006.
659	[31]	Duschek S, Nassauer L, Montoro CI, Bair A, Montoya P. Dispositional empathy is
660		associated with experimental pain reduction during provision of social support by
661		romantic partners. Scand J Pain 2019;20:205–9. https://doi.org/10.1515/sjpain-2019-
662		0025.
663	[32]	Dionne C, Koepsell TD, Korff M Von, Deyo RA, Barlow WE, Checkoway H. Formal
664		Education and Back-Related Disability. Spine (Phila Pa 1976) 1995;20:2721–30.
665		https://doi.org/10.1097/00007632-199512150-00014.
666	[33]	van der Heide I, Wang J, Droomers M, Spreeuwenberg P, Rademakers J, Uiters E. The
667		Relationship Between Health, Education, and Health Literacy: Results From the Dutch
668		Adult Literacy and Life Skills Survey. J Health Commun 2013;18:172–84.
669		https://doi.org/10.1080/10810730.2013.825668.
670	[34]	Meints SM, Edwards RR. Evaluating psychosocial contributions to chronic pain
671		outcomes. Prog Neuropsychopharmacol Biol Psychiatry 2018;87:168–82.
672		https://doi.org/10.1016/j.pnpbp.2018.01.017.
673	[35]	Patterson AL, Gritzner S, Resnick MP, Dobscha SK, Turk DC, Morasco BJ. Smoking
674		Cigarettes as a Coping Strategy for Chronic Pain Is Associated With Greater Pain

44

Supporting information

690

691 **S1 Fig. Top 20 questions.** The 20 most important questions for accurate cluster prediction. 692 S2A Fig. Hierarchical clustering dendogram of the development cohort University 693 Medical Center Utrecht. Hierarchical cluster analysis showing three clusters: Cluster 1(red), 694 Cluster 2 (blue) and Cluster 3 (green). X-axis representing the individual questions of three 695 questionnaires (Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale 696 (PCS), and Tampa Scale of Kinesiophobia (TSK). Y-axis representing included patients. 697 S2B Fig. Hierarchical clustering dendogram of the validation cohort Erasmus MC 698 Hierarchical cluster analysis showing three clusters: Cluster 1(red), Cluster 2 (blue) and 699 Cluster 3 (green). X-axis representing the individual questions of three questionnaires 700 (Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and 701 Tampa Scale of Kinesiophobia (TSK). Y-axis representing included patients. 702 S1 Table. Frequencies of the 10 most common diagnoses in each cluster (validation 703 **cohort Erasmus MC)** 704 Data expressed as percentage per cluster. Significance levels computed by Pearson-Chi 705 square. 706 S2 Table. Sociodemographics, pain intensity, duration, character, interference and 707 health-related quality of life in the validation cohort (Erasmus Medical Center 708 **Rotterdam) and comparison among the clusters** 709 Data expressed as mean (95% confidence interval), median (interquartile range) or count (%). 710 Statistics computed by one-Way ANOVA Test or Pearson Chi Square. P-values ≤ 0.01 are in 711 bold. Effect sizes for categorical data are calculated with Eta-squared test or Cramer's V. 712 Effect sizes computed by Eta-squared test indicate a small effect 0.01 to 0.06, medium 0.06 to 713 0.14 and large effect ≥0.14. Effect sizes with Cramer's V indicate a small effect 0.1 to 0.3,

S3D Table. Prediction characteristics for the validation cohort Erasmus MC using the

10 questions

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

737

